CClinicalTrials.gg
CompletedNCT07718256TURPUpdated Jul 31, 2026

Bipolar Enucleation of the Prostate Versus Bipolar TURP

An interventional study of bTURP and BEEP in Benign Prostate Hypertrophy(BPH), sponsored by Ain Shams University. Completed at 1 site in Egypt. Open to male participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by Ain Shams University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Jul 2025, registered Jul 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
Male
01

Study summary

Bipolar enucleation of the prostate (BEEP) was introduced to treat patients with large prostate. The study compared the functional outcomes and perioperative complications of bipolar TURP and bipolar enucleation of large prostates above 80 gm.

Read the detailed description

Recent literature suggests that enucleation techniques may provide superior functional results, reduced bleeding, and lower retreatment rates. Nevertheless, there remains limited high-quality randomized controlled data directly comparing bipolar TURP and bipolar enucleation of prostate as a head to head comparison regarding functional outcomes and peri-operative complications.

In this study, a randomized controlled trial was performed to compare bipolar enucleation of the prostate versus bipolar transurethral resection of the prostate in BPH regarding symptoms relief, residual adenoma, urine flow rate and post-operative morbidity.

02

Conditions studied

  • Benign Prostate Hypertrophy(BPH)

Browse trials for

03

In context

Prostatic Hyperplasia

783 studies on the registry are indexed under Prostatic Hyperplasia; 174 are open to participants now.

This study's enrollment of 120 is above the median of 97 across 593 interventional studies indexed under Prostatic Hyperplasia.

Browse Prostatic Hyperplasia studies →

Lead sponsor

Ain Shams University is the lead sponsor of 1,876 studies on the registry; 423 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

  • All male patients above the age of 40 years who presented to the urology clinic in Ain Shams university hospitals with BPH with prostate size 80 - 120 g and have any of the following criteria:
  • Voiding symptoms that are poorly responsive to medical treatment (IPSS more than 18 and Qmax less than 15 ml/sec)
  • Persistent or recurrent attacks of urine retention due to BPH.
  • Large bladder stones from BPH.
  • Recurrent UTI due to BPH.
  • Severe gross hematuria from BPH.

Exclusion criteria

Exclusion Criteria:

  • Patients with untreated or active UTI.
  • Previous pelvic radiation or pelvicl trauma.
  • Patients with anesthesia contraindications such as uncontrolled diabetes mellitus, severe coagulation disorders and severe cardiac diseases.
  • Known or suspected neurogenic bladder.
  • Urethral stricture or urethral cancer.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Active comparator
    bipolar TURP

    transurethral resection of the prostate by bipolar current

    Procedure: bTURP

  • Active comparator
    BEEP

    endoscopic enucleation of the prostate by bipolar current

    Procedure: BEEP

Interventions

  • ProcedurebTURP

    transurethral resection of the prostate by bipolar current

    Also known as: TURIS

  • ProcedureBEEP

    endoscopic enucleation of the prostate by bipolar current

    Also known as: TUEP

06

What researchers measure

Primary outcomes

  1. volume of residual prostatic adenoma

    measurement of volume of residual prostatic adenoma post bipolar TURP and BEEP was done by pelvi-abdominal ultrasound

    Time frame: one month postoperative

  2. change in international prostate symptoms score

    The international prostate symptoms score is a patient-completed questionnaire for standardized assessment of lower urinary tract symptoms (LUTS). It includes seven questions that evaluate the following urinary symptoms: * Weak urinary stream (0 : 5) * Incomplete bladder emptying (0 : 5) * Straining during urination (0 : 5) * Intermittent urine flow (0 : 5) * Increased urinary frequency (0 : 5) * Urgency (0 : 5) * Nocturia (0 : 5) Grade 1 (score = 0 - 7) : Mild LUTS Grade 2 (score = 8 - 19) : Moderate LUTS Grade 3 (score = 20 - 35) : Severe LUTS

    Time frame: pre-operative, one, three, six and twelve months postoperative

  3. change in maximum urine flow rate(Q max)

    Maximum urine flow rate was evaluated by Uroflowmetry

    Time frame: pre-operative, 1, 3, 6 and 12 months postoperative

Secondary outcomes

  1. change in post voiding residual urine

    post voiding residual urine in bladder was evaluated by Trans-abdominal ultrasound

    Time frame: pre-operative, 1, 3, 6 and 12 months postoperative

  2. operation time

    Operation time was calculated from insertion of the cystoscope/resectoscope into the urethra to final removal of the scope

    Time frame: during operation

07

Study locations

1 site
  • Ain Shams university hospitals
    Cairo, Cairo Governorate 11566, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07718256
Lead sponsor
Ain Shams University
Responsible party
Amgad Abdel Aziz (Principal Investigator, Ain Shams University) — Principal investigator
First posted
Jul 21, 2026
Start date
Jul 1, 2025
Primary completion
Jun 30, 2026
Completion
Jul 14, 2026
Last update
Jul 31, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion